Stay updated on COX & EGFR Inhib. in Polyposis Clinical Trial

Sign up to get notified when there's something new on the COX & EGFR Inhib. in Polyposis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the COX & EGFR Inhib. in Polyposis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:34:29.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) patients in a clinical trial testing the combination of sulindac and erlotinib.
    Difference
    0.1%
    Check dated 2024-06-06T14:45:54.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    24%
    Check dated 2024-05-22T21:28:06.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:36:00.000Z thumbnail image

Stay in the know with updates to COX & EGFR Inhib. in Polyposis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the COX & EGFR Inhib. in Polyposis Clinical Trial page.